Antonio Passaro: An important milestone in the treatment of advanced NSCLC with common EGFR mutations
Antonio Passaro, Medical oncologist at the European Institute of Oncology in Milan, posted on LinkedIn:
“Today marks an important milestone in the treatment of advanced NSCLC with common EGFR mutations. The European Medicines Agency has approved the first chemo-free combination therapy – amivantamab and lazertinib – as a first-line treatment for patients with advanced o metastatic NSCLC harboring common EGFR mutations (exon 19 deletions or exon 21 L858R mutations).
This decision is not just about introducing a new therapy; it’s about fundamentally rethinking how we approach care for patients. While we await the results on overall survival, which will further define and potentially qualify the robustness of this benefit, this new regimen brings a breath of innovation and progress, offering a significant opportunity for patients and their families.
This approval confirms the dedication and expertise of our entire IEO team in developing this combination through the MARIPOSA study in favor of our patients. Today’s milestone further reinforces IEO’s leadership and our steadfast commitment to advancing the treatment of patients with NSCLC carrying EGFR mutations.”
Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. He focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC). Dr. Antonio Passaro is an Associate Editor for Lung Cancer Journal by Elsevier and the Chair of the ESMO Press & Media Affairs Committee. He is also a faculty member for the Lung and Other Thoracic Tumours faculty group and the ESMO-MCBS Extended Working Group. He also holds editorial positions and key roles in societies like ESMO and AIOM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023